Table 2.
Type of cells | Origin of cells | Cell line | Cytopathic effect | Viral antigen |
---|---|---|---|---|
Fibroblasts | Lung fibroblast | M426 (ATCC PTA-5244) | CPE+ | IFA+ |
Primary human foreskin fibroblasts | – | CPE+ | IFA+ | |
Epithelial cells | Cervical cancer | HeLa (ATCC CCL-2) | CPE+ | IFA+ |
Embryonal kidney | 293 (ATCC CRL-1573) | CPE+ | IFA+ | |
Breast adenocarcinoma | MCF7 (ATCC HTB-22) | CPE+ | IFA+ | |
Melanoma | MEWO (ATCC HTB-65) | ∗CPE-/+ | ∗IFA-/+ | |
Neural cells | Glioblastoma-astrocytoma | U87 (ATCC HTB-14) | CPE+ | IFA+ |
Glioblastoma | A-172 (ATCC CRL-1620) | CPE+ | IFA+ | |
Leukocytes | Human cord blood mononuclear cells (primary) | – | Degeneration, No CPE | IFA+ |
Adult human peripheral blood lymphocytes (primary) | – | Degeneration, No CPE | IFA+ | |
B-lymphocytes | Mature B-cell line | Bjab (DSMZ ACC 757) | No CPE | IFA+ |
EBV transformed B-cell line | LCL- 8664 (ATCC CRL-1085) | No CPE | IFA+ | |
Human histiocyte lymphoma | U937 (ATCC CRL-1593.2) | No CPE | IFA+ | |
T-lymphocytes | Acute lymphoblastic leukemia | MOLT-3 (ATCC CRL-1552) | No CPE | IFA+ |
Acute lymphoblastic leukemia | HSB-2 (ATCC CCL-120.1) | No CPE | IFA+ | |
Lymphoblastic lymphoma | Sup-T1 (ATCC CRL-1942) | No CPE | IFA+ | |
Acute T-cell leukemia | E6.1 (ATCC TIB-152) | No CPE | IFA+ |
ATCC, American type culture collection; ECACC, European collection of cell cultures; DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH/German collection of microorganisms and cell cultures; CPE, cytopathic effect; IFA, immunofluorescent antibody; IHC, immunohistochemistry. ∗MEWO, intracellular virus antigens and cytopathic effect developed from 7 days Postinfection.